A comprehensive analysis of 2,737 genomes reorganizes the Mycobacterium avium complex into fifteen species-level clusters and ...

Newswise — San Diego, Calif. – This week at the ATS 2024 International Conference, researchers announced results from three clinical trials – the ARISE Study on amikacin liposome inhalation suspension ...

November 11, 2009 (Philadelphia, Pennsylvania) — A subset of patients with solid organ malignancies and pulmonary Mycobacterium avium–complex (MAC) infections might fare worse if the infection is ...

Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Supplemental New Drug Application (sNDA) for review of ARIKAYCE (amikacin liposome inhalation ...

Mycobacterium avium complex (MAC) is a group of bacteria related to tuberculosis. These germs are very common in food, water, and soil. Almost everyone has them in their bodies. When you have a strong ...

New research from Norway has shown that Mycobacterium avium does not infect pigs via birds, as previously believed. M. avium can be divided into several subspecies, and the research shows that birds ...

ELISA-based assay testing offers a practical, high-throughput approach for early detection of Mycobacterium avium subsp. paratuberculosis(MAP), the causative agent of Johne’s disease (JD), ...

Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...

The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium ...

Treatment for mycobacterium avium complex (MAC) depends on where the infection is. Your doctor will also consider how serious your symptoms are and other medical conditions you may have. Here’s what ...